US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

29.72

+0.57681.98%

Post-market: 29.720.00000.00%16:10 EDT

Volume:489

Turnover:14.43K

Market Cap:2.67M

PE:- -

High:29.72

Open:29.47

Low:29.47

Close:29.14

52wk High:29.72

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.60

T/O Rate:0.54%

Dividend:0.92

Dividend Rate:3.09%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

PDS Biotech Reports Second Quarter 2026 Financial Results

CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial

From petri dish to patient:biotech’s formidable obstacle course

The West Australian

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy

Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Press Release: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Press Release: Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/NVIB/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":29.716,"timestamp":1791230400000,"preClose":29.1392,"halted":0,"volume":489,"hourTrading":{"tag":"盘后","latestPrice":29.716,"preClose":29.716,"latestTime":"16:10 EDT","volume":7,"amount":208.012,"timestamp":1791231005191,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01979464089611253,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Post-Mkt","change":0.5768,"latestTime":"10-05 17:34:05 EDT","open":29.465,"high":29.716,"low":29.465,"amount":14431,"amplitude":0.008614,"askPrice":44.05,"askSize":100,"bidPrice":14.89,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791244800000},"marketStatusCode":4,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":29.1392,"nav":29.11,"aum":2619962.27,"dividendRate":0.030899,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.716,"preClose":29.716,"latestTime":"16:10 EDT","volume":7,"amount":208.012,"timestamp":1791231005191,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.601624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.601624,"shares":90001,"dividePrice":0.9182,"high":29.716,"amplitude":0.008614,"preClose":29.1392,"low":29.465,"week52Low":24.54,"pbRate":"--","week52High":29.716,"institutionHeld":0,"latestPrice":29.716,"committee":0.333333,"eps":0,"divideRate":0.030899,"volume":489,"delay":0,"ttmEps":0,"open":29.465,"prevYearClose":25,"prevWeekClose":29.1392,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":28.5219,"twentyDayClose":28.8896},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","IND","GDOC","BK4539","NVIB","BK4568","BK4551","IDNA","BK4535","BK4232","MEDX","BK4585","BK4139","BK4588","BNTX","HYLG","R","IVVD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNCR","BK4585","NVIB","BK4161","MEDX","LD","BK4211","BK4195","IDNA","BK4588","ORR","BK4230","PFS","FBT","CR","BK4539","SYNB","GDOC","CAR","BK4022","HYLG","TBXU","IBBQ","GNOM","BK4139","LFSC","IBB","CRBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152369","title":"PDS Biotech Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152369?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4092","IDNA","BK4585","NVIB","HYLG","BK4588","XBI","ORR","BK4581","BK4211","PDS","GDOC","MEDX","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659613658","title":"CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659613658","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659613658?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:12","pubTimestamp":1786601532,"startTime":"0","endTime":"0","summary":"Amur Minerals ( ($GB:CRTX) ) has shared an announcement. CRISM Therapeutics has completed the Site Initiation Visit at its lead NHS clinical trial ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","IDNA","GDOC","BK4139","BK4007","MEDX","NVIB","HYLG","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131647","title":"From petri dish to patient:biotech’s formidable obstacle course","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131647","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659131647?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:12","pubTimestamp":1786576331,"startTime":"0","endTime":"0","summary":"A biotech breakthrough can be worth billions – if it survives the journey. Bulls N’ Bears follows the trek from a promising discovery through to a product doctors can actually use.","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-22720423/37f3ab3f7c773a9a699efc346c96f6d2e782abe6.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22720423/37f3ab3f7c773a9a699efc346c96f6d2e782abe6.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/from-petri-dish-to-patientbiotechs-formidable-obstacle-course-c-22720423","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/from-petri-dish-to-patientbiotechs-formidable-obstacle-course-c-22720423","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["NVIB","XBIX","EES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LABU","NVIB","IDNA","BK4139","LFSC","MEDI","MRNY","LENZ","GNMX","RSPH","IEIH","FRTY","MRNX","GDOC","TBXU","BK4539","XLVX","BBP","BK4588","PSCH","PINK","SYNB","IYH","BK4585","BMED","TECB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907259","title":"Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907259?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"-- On track for September 2026 top-line results from Phase 2b clinical trial.  evaluating laromestrocel as a potential adjunct treatment for. hypoplastic left heart syndrome , a rare pediatric disease and. -- Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE. Healthspan competition based on published clinical trial results which. indicated laromestrocel increased 6-minute walk distance in patients with. -- Three new independent Directors join Longeveron's Board of Directors. laromestrocel as a potential adjunct therapy for HLHS are anticipated in. -- In May, the Company announced that the U.S. Food and Drug Administration.  held a Type C meeting in late March 2026 focused on the ELPIS II. Phase 2b clinical trial and upcoming data readout.-- Also in May, the Company announced that the independent Data Monitoring. Committee  completed its final prespecified data review for ELPIS II. Phase 2b clinical trial . The DMC performed a risk-benefit. assessment, indicated n","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BK4139","BK4022","AD","BK4081","EMA","HYLG","IDNA","LGVN","R","BK4232","NVIB","MEDX","DMC","BK4189","IND","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658700929","title":"NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658700929","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658700929?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:08","pubTimestamp":1786540125,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs Inc., a clinical-stage biotech and majority-owned subsidiary of SciSparc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BBC","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972189","title":"Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972189?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"double-blind, placebo-controlled global trial evaluating two doses of. AP01 dosed twice daily in patients with progressive pulmonary fibrosis. . This 52-week trial is designed to assess safety and efficacy of. AP01, with a primary endpoint of change in lung function measured by. forced vital capacity . The study overenrolled beyond its target. enrollment of 375, with a total of 398 patients randomized into three. treatment cohorts. Topline data are anticipated in the second half of. -- In September 2026, the Company plans to present two abstracts at the ERS. Congress in Barcelona, Spain. The first poster will highlight data. modeling effective AP01 distribution throughout the target tissue in both. healthy and idiopathic pulmonary fibrosis  lungs. The second poster. will describe the integration of patient perspectives into clinical trial. design. Detailed poster session information will be provided in advance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FVC","IDNA","AVLN","BK4007","HYLG","GDOC","MEDX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658089139","title":"Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658089139","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658089139?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Socie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343572/0/en/avalyn-reports-second-quarter-2026-financial-results-and-recent-business-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","GDOC","FVC","IDNA","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658390895","title":"Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658390895","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658390895?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343555/14025/en/arbutus-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","NVIB","HYLG","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","IND","MEDX","PWS","GDOC","AARD","BK4007","NVIB","IDNA","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194913","title":"Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194913","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658194913?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:05","pubTimestamp":1786453500,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342811/0/en/longeveron-named-a-finalist-team-and-will-receive-a-1-000-000-milestone-2-award-for-the-xprize-healthspan-global-competition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4150","BK4120","AD","BK4139","GDOC","MEDX","LGVN","BK4575","BK4132","HYLG","NVIB","TISI","MSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658099084","title":"Press Release: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658099084","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658099084?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:01","pubTimestamp":1786449660,"startTime":"0","endTime":"0","summary":"reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment. -- New manufacturing batch completed including process enhancements that. have further reduced already low levels of process impurities.-- Kalaris is currently conducting a Phase 1b/2, multi-ascending dose,The study aims to assess the safety and efficacy of repeat doses of TH103. at different dose levels and to identify the optimal dose and regimen for. potential Phase 3 development. Preliminary data from the Phase 1b/2 study. is expected in the first half of 2027.-- As previously announced, Kalaris expanded its leadership team with the. hire of Liisa Bayko as Chief Financial Officer. Ms. Bayko brings more. than two decades of experience in biotechnology finance, strategy, and. capital markets, most recently serving as Managing Director and Senior. Biotechnology Analyst at Evercore ISI, where she was consistently. recognized as one of the industry's top-ranked analysts covering small-. -- As announced recently, ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","MEDX","HYLG","KLRS","BK4139","BMED","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990407","title":"IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990407","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990407?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Pha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342668/0/en/imunon-reports-second-quarter-2026-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","GDOC","NVIB","HYLG","BK4139","IMNN","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990336","title":"Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990336?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"Phase 2a clinical trial entitled \"A Phase IIa, single-arm, single-center,-- The VIRAGE2 study design incorporates feedback from both the. European Medicines Agency  and the U.S. Food and Drug. VIRAGE Phase 2b trial in metastatic PDAC patients treated with 2. repeated dosing of VCN-01 may provide additional clinical benefit.-- The VIRAGE2 trial will evaluate the safety and feasibility of. administering at least 3 doses of VCN-01 given approximately 2. The trial is expected to enroll 6 evaluable patients. Results from. the VIRAGE2 study will inform the VCN-01 dosing regimen for","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0210528500.USD","TOVX","L","BK4081","LU2487616109.SGD","GDOC","BK4139","BK4555","BK4585","MEDX","TM","03160","BK4604","BK4107","BK4099","NVIB","LU0053666078.USD","EMA","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658447990","title":"Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658447990","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658447990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342635/0/en/kalaris-reports-second-quarter-2026-financial-results-and-provides-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","GDOC","HYLG","BMED","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992080","title":"Press Release: Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992080","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992080?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":"advance denifanstat in moderate to severe acne for the U.S., prioritizing. -- Equity financing: In April 2026, the Company completed an underwritten. equity financing resulting in $175.0 million of gross proceeds, before. deducting underwriting discounts and commissions and other offering. -- Russell Index inclusion: Sagimet was added to the broad-market Russell. 3000 Index and small-cap Russell 2000 Index effective June 29,-- TVB-3567: A first-in-human Phase 1 clinical trial of FASN inhibitor. -- KOL event: On April 30, 2026, the Company hosted a Key Opinion Leader. event with Julie Harper, MD, founding Director and past President of. the American Acne and Rosacea Society, discussing the acne treatment. landscape and Sagimet's planned Phase 3 clinical trial. A recording of. the event is accessible at this link.Publications and Presentations-- Data showing that Sagimet's FASN inhibitors reduced de novo lipid levels. in human sebocytes were presented at the 83rd Society for Investigativ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","GDOC","HYLG","BK4022","BK4139","SGMT","R","NVIB","BK4232","00511","BK1145"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658799280","title":"Press Release: Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658799280","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658799280?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"directly targeting the underlying sarcomeric defects in genetic dilated. --  Danicamtiv is currently being evaluated in the Company's KINSHIP-DCM. --  Preclinical and clinical evidence linking danicamtiv treatment to. improvements in right ventricular function to be presented at the. upcoming European Society of Cardiology Congress . [Session:. Late-Breaking Basic and Translational Science; Sunday, Aug. 30th at 8:15. --  In July, the Company completed enrollment of Cohort 1 (myosin heavy. chain 7, or MYH7, and titin, or TTN, patients) of the Phase 2b. KINSHIP-DCM clinical trial and enrollment of the Phase 3 portion is now. underway. The Company expects to share Phase 2b topline data in the first. half of 2027.Ataciguat: soluble guanylate cyclase  activator in development for CAVS--  Ataciguat targets valvular interstitial cells to slow osteogenic and. calcific remodeling, an underlying driver of disease progression in. calcific aortic valve stenosis , and has demonstrated direct. myoca","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","ASH","03160","BK4109","BK4099","BK4555","KARD","MEDX","TM","BK4007","GDOC","BK4588","IDNA","BK4604","HYLG","BK4585","AGT","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952508","title":"Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952508","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952508?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393200,"startTime":"0","endTime":"0","summary":"Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342259/0/en/palisade-bio-reports-second-quarter-2026-financial-results-and-highlights-continued-advancement-of-pali-2108-into-phase-2-development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","BK4006","GDOC","IDNA","IE00BZ1G4Q59.USD","LU0170899867.USD","IBD","LU0971096721.USD","BK4139","BK4127","LU2237443622.USD","BK4023","IE00BFXG1179.USD","BK4116","CMC","IND","LU2237443895.HKD","BK4007","LU0267386448.USD","LU2746668461.USD","LU0882574139.USD","PD","LU2237443978.SGD","LU2237443549.SGD","IE00BHPRN162.USD","LU2237443382.USD","MEDX","LU1363072403.SGD","LU2746668974.SGD","PALI","HYLG","LU0149725797.USD","NVIB","CD","LU1169590202.USD","IE00BKVL7J92.USD","LU2237443465.HKD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}